Centrix Pharmaceutical announces Clofera™,
a unique antitussive and nasal
decongestant for the temporary relief of cough and nasal congestion
August 14, 2009 – BIRMINGHAM, Ala. – Centrix Pharmaceutical,
Inc., a privately-held specialty pharmaceutical company focused
on Pediatrics and Women's Health, announced
plans to commercially launch Clofera™ for the temporary
relief of cough and nasal congestion.
Clofera™ is indicated
for the temporary relief of cough and nasal congestion due
to the common cold, hay fever, or other upper respiratory allergies.
Clofera™ contains
a non-narcotic antitussive, chlophedianol hydrochloride, in
addition to nasal decongestant, pseudoephedrine hydrochloride.
The product is specifically formulated without dyes, sugar,
alcohol or gluten to meet particular consumer needs and address
patient sensitivities. Clofera™ is expected to release
during the beginning of the fourth quarter.
"We are pleased
to introduce Clofera to temporarily control the cough reflex,
therefore reducing the intensity of coughing with a product
that is free of narcotic effects. Clofera provides physicians
with another therapeutic option in the management of cough
and congestion associated with allergic rhinitis or the common
cold. The release of Clofera further compliments our goal to
develop and expand the Centrix specialty portfolio," stated
John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.
About
Clofera™
Clofera™ temporarily controls the cough reflex, temporarily
relieves nasal congestion, swollen nasal passages, sinus congestion
and pressure. Clofera™ should
not be used in patients taking monoamine oxidase inhibitors
or with known hypersensitivity to any of the components of
the product. Patients with a chronic cough, asthma, emphysema,
mucus production, heart disease, high blood pressure, thyroid
disease, diabetes, or enlarged prostate should consult physician
before use. Recommended dosage should not be exceeded. Clofera™ contains
no dextromethorphan, antihistamines, sugar, alcohol, or dyes
and is gluten free. Clofera™ will be available in grape
flavor.
About Centrix Pharmaceutical, Inc.
Centrix Pharmaceutical is a privately-held specialty pharmaceutical
company focused in Pediatrics and Women's Health. Headquartered
in Birmingham, AL, the Company's products are marketed
by its dedicated sales force in the United States. For more
information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.
Centrix announces ongoing expansion of its U.S. sales force
during the second half of 2008. The plan calls for increased
presence in women's health and pediatric markets through
the addition of eight new territories located in high volume
strategic markets. This sales force expansion enables Centrix
to continue a strong engagement with physicians and a more
solution-focused approach for patients.
"We want to provide greater value to our customers as we continue
to extend our reach, develop our pipeline and strengthen our
sales organization. Our dedicated employees are our greatest
asset and that's the driving force behind this expansion,"
President and CEO, Bob Booth stated. Next phases of the sales
force and product portfolio expansion are expected to take
place in the second half of 2009.
Centrix Enters Agreement with JSJ Pharmaceuticals
To Co-Promote Inova® Acne Control Therapy (Benzol Peroxide/Salicylic
Acid) Easy Pads®
Inova® Easy Pad® showed
no irritation on 52 subjects over a 3 week trial period. The
Inova® Easy Pad® formulation
was proven safe with little to no irritation in a 3 week study
of 53 subjects. During this trial period no adverse reaction
or symptoms were reported. Inova 2% showed
excellent results in 60% of patients and good results in 38%
of patients.
Patient Rebate Coupons Available To Help With Medication
Cost
To help patients with the cost of their medication Centrix
is pleased to announce the introduction of patient rebate coupons.
Rebates of $10.00 to $35.00 per prescription are available
for the following products:
